Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Contributeurs/tricesBottomley, Andrew; Coens, Corneel; Mierzynska, Justyna; Blank, Christian U; Mandalà, Mario; Long, Georgina V; Atkinson, Victoria G; Dalle, Stéphane; Haydon, Andrew M; Meshcheryakov, Andrey; Khattak, Adnan; Carlino, Matteo S; Sandhu, Shahneen; Puig, Susana; Ascierto, Paolo A; Larkin, James; Lorigan, Paul C; Rutkowski, Piotr; Schadendorf, Dirk; Koornstra, Rutger; Hernandez-Aya, Leonel; Di Giacomo, Anna Maria; van den Eertwegh, Alfonsus J M; Grob, Jean-Jacques; Gutzmer, Ralf; Jamal, Rahima; van Akkooi, Alexander C J; Krepler, Clemens; Ibrahim, Nageatte; Marreaud, Sandrine; Kicinski, Michal; Suciu, Stefan; Robert, Caroline; Eggermont, Alexander M M; EORTC Melanoma Group
Collaborateurs/tricesBoehncke, Wolf-Henning
Publié dansLancet. Oncology, vol. 22, no. 5, p. 655-664
Date de publication2021-05
Date de mise en ligne2021-04-12
Résumé
Mots-clés
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized / therapeutic use
- Double-Blind Method
- Female
- Humans
- Male
- Melanoma / drug therapy
- Melanoma / mortality
- Melanoma / pathology
- Melanoma / psychology
- Middle Aged
- Neoplasm Staging
- Quality of Life
- Skin Neoplasms / drug therapy
- Skin Neoplasms / mortality
- Skin Neoplasms / pathology
- Skin Neoplasms / psychology
Structure d'affiliation
Groupe de recherche
Citation (format ISO)
BOTTOMLEY, Andrew et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. In: Lancet. Oncology, 2021, vol. 22, n° 5, p. 655–664. doi: 10.1016/S1470-2045(21)00081-4
Fichiers principaux (1)
Article (Published version)
Fichiers secondaires (1)
Identifiants
- PID : unige:159804
- DOI : 10.1016/S1470-2045(21)00081-4
- PMID : 33857414
Jeu de données
ISSN du journal1470-2045